GR900100582A - Μέ?οδοι και συν?έσεις για την βελτίωση των συμπτωμάτων της σήψης. - Google Patents

Μέ?οδοι και συν?έσεις για την βελτίωση των συμπτωμάτων της σήψης.

Info

Publication number
GR900100582A
GR900100582A GR900100582A GR900100582A GR900100582A GR 900100582 A GR900100582 A GR 900100582A GR 900100582 A GR900100582 A GR 900100582A GR 900100582 A GR900100582 A GR 900100582A GR 900100582 A GR900100582 A GR 900100582A
Authority
GR
Greece
Prior art keywords
sepsis
recommendations
symptoms
improving
methods
Prior art date
Application number
GR900100582A
Other languages
English (en)
Other versions
GR1003164B (el
Inventor
John C Mathison
Peter Tobias
Richard Ulevitch
Samuel D Wright
Original Assignee
Scripps Clinic Res
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Clinic Res, Univ Rockefeller filed Critical Scripps Clinic Res
Publication of GR900100582A publication Critical patent/GR900100582A/el
Publication of GR1003164B publication Critical patent/GR1003164B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Two-Way Televisions, Distribution Of Moving Picture Or The Like (AREA)

Abstract

Η παρούσα εφεύρεσις αφορά εις μέθοδον θεραπείας της σήψεως, περιλαμβάνουσα την χορήγησιν μιας θεραπευτικώς αποτελεσματι- κής ποσότητος μορίων αντισώματος αντι-CD14. Θεωρείται επίσης μια θεραπευτική σύνθεσις περιέχουσα μόρια αντισώματος αντι- CD14 εντός φαρμακευτικώς αποδεκτού φορέως. ω
GR900100582A 1989-08-01 1990-08-01 Μεθοδοι και συνθεσεις για την βελτιωση των συμπτωματων της σηψης. GR1003164B (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38781789A 1989-08-01 1989-08-01

Publications (2)

Publication Number Publication Date
GR900100582A true GR900100582A (el) 1991-12-30
GR1003164B GR1003164B (el) 1999-07-05

Family

ID=23531466

Family Applications (1)

Application Number Title Priority Date Filing Date
GR900100582A GR1003164B (el) 1989-08-01 1990-08-01 Μεθοδοι και συνθεσεις για την βελτιωση των συμπτωματων της σηψης.

Country Status (14)

Country Link
US (4) US5730980A (el)
EP (1) EP0485430B1 (el)
JP (1) JP2744130B2 (el)
AT (1) ATE171042T1 (el)
AU (1) AU645515B2 (el)
CA (1) CA2022429C (el)
DE (1) DE69032662T2 (el)
DK (1) DK0485430T3 (el)
ES (1) ES2120948T3 (el)
FI (1) FI920450A0 (el)
GR (1) GR1003164B (el)
IE (1) IE902770A1 (el)
PT (1) PT94869B (el)
WO (1) WO1991001639A1 (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0485430T3 (da) * 1989-08-01 1999-06-14 Scripps Research Inst Fremgangsmåder og sammensætninger til bedring af symptomer på sepsis
DE4029227A1 (de) * 1990-09-14 1992-03-19 Imtox Gmbh Arzneimittel enthaltend cd14
EP0634935A4 (en) * 1992-04-06 1996-01-31 North Shore Univ Hospital A NEW THERAPY OF SEPSIS BY MEANS OF A SOLUBLE FORM OF RECOMBINANT CD14 MYELOMONOCYTIC ANTIGEN.
US5820858A (en) * 1993-05-28 1998-10-13 The Scripps Research Institute Methods and compositions for inhibiting CD14 mediated cell activation
WO1995000641A1 (en) 1993-06-17 1995-01-05 Xoma Corporation Lipopolysaccharide binding protein derivatives
US5484705A (en) * 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
US5891618A (en) 1994-01-24 1999-04-06 Xoma Corporation Method for quantifying LBP in body fluids
ATE308994T1 (de) * 1994-09-16 2005-11-15 Scripps Research Inst Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien
US5766593A (en) * 1994-12-30 1998-06-16 Amgen Inc. Anti-inflammatory CD14 peptides
WO1996020957A1 (en) * 1994-12-30 1996-07-11 Amgen Inc. Anti-inflammatory cd14 polypeptides
WO1996032418A1 (en) * 1995-04-13 1996-10-17 Laboratoires Om S.A. Anti-cd14 antibodies for use in the induction of il-10 secretion
AU6392996A (en) * 1995-06-19 1997-01-15 Sanna M. Goyert A method for inhibiting bacteremia and bacterial dissemination
DE69703689T2 (de) 1996-05-10 2001-05-10 Xoma Technology Ltd., Berkeley Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
NZ332954A (en) * 1996-05-23 2000-07-28 Xoma Corp Use of BPI protein products to treat humans with hemorrhage due to trauma
US6093693A (en) * 1996-11-18 2000-07-25 The Wellesley Hospital Foundation B cell activation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US5990082A (en) 1997-10-22 1999-11-23 Xoma Corporation Uses of lipopolysaccharide binding protein
DK1052984T3 (da) * 1998-02-07 2004-09-20 Vernalis Oxford Ltd Antibakterielle midler
ID26730A (id) * 1998-05-27 2001-02-01 Gemma Biotechnology Ltd Induksi protein-protein dan peptida-peptida antibiotik oleh lait/scd14-protein
US6974698B1 (en) * 1999-01-15 2005-12-13 The United States Of America As Represented By The Department Of Health And Human Services Methods for delivering biologically active molecules into cells
EP1213586A4 (en) 1999-09-17 2003-02-05 Mochida Pharm Co Ltd METHOD FOR FRACTIONAL MEASUREMENT OF SOLUBLE CD14 PROTEIN
AU2001290315A1 (en) * 2000-11-22 2002-06-03 Mochida Pharmaceutical Co., Ltd. Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding
EP1348443A4 (en) * 2000-12-08 2005-07-06 Takeda Pharmaceutical COMBINED MEDICINES
WO2003105898A1 (en) * 2002-06-14 2003-12-24 Centocor, Inc. Modified "s" antibodies
EP2266606B1 (en) * 2003-05-15 2014-09-10 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
AU2006218876A1 (en) * 2005-02-28 2006-09-08 Centocor, Inc. Heterodimeric protein binding compositions
US7696211B2 (en) * 2005-04-29 2010-04-13 Wilson Constance N Methods and pharmaceutical compositions for treating sepsis
CA2609262A1 (en) 2005-06-03 2006-12-07 Mochida Pharmaceutical Co., Ltd. Anti-cd14 antibody fusion protein
WO2015140591A1 (en) * 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
IL309046B2 (en) * 2017-04-21 2025-03-01 Implicit Bioscience Ltd CD14 antagonist antibodies for the treatment of neurodegenerative diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057598A (en) * 1983-05-06 1991-10-15 Centocor, Inc. Monoclonal antibodies reactive with endotoxin core
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
US4834976A (en) * 1986-07-03 1989-05-30 Genetic Systems Corporation Monoclonal antibodies to pseudomonas aeruginosa flagella
DK0485430T3 (da) * 1989-08-01 1999-06-14 Scripps Research Inst Fremgangsmåder og sammensætninger til bedring af symptomer på sepsis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF CELL BIOLOGY vol. 109, September 1989, pages 1341 - 1349 C. NATHAN ET AL. 'CYTOKINE-INDUCED RESPIRATORY BURST OF HUMAN NEUTROPHILS: DEPENDENCE ON EXTRACELLULAR MATRIX PROTEINS AND CD11/CD18 INTEGRINS' THE WHOLE ARTICLE *
JOURNAL OF CLINICAL INVESTIGATION vol. 81, June 1988, J. C. MATHISON ET AL. 'PARTICIPATION OF TUMOR NECROSIS FACTOR IN THE MEDIATION OF GRAM NEGATIVE BACTERIAL LIPOPOLYSACCHARIDE-INDUCED INJURY IN RABBITS' THE WHOLE ARTICLE *
JOURNAL OF EXPERIMENTAL MEDICINE vol. 170, October 1989, pages 1231 - 1241 S.D. WRIGHT ET AL. 'LIPOPOLYSACCHARIDE (LPS) BINDING PROTEIN OPSONIZES LPS-BEARING PARTICLES FOR RECOGNITION BY A NOVEL RECEPTOR ON MACROPHAGES' THE WHOLE ARTICLE *
NEW ENGLAND JOURNAL OF MEDICINE vol. 316, no. 7, 12 February 1987, pages 379 - 385 B. BEUTLER ET AL. 'CACHECTIN: MORE THAN A TUMOR NECROSIS FACTOR' *

Also Published As

Publication number Publication date
ES2120948T3 (es) 1998-11-16
IE902770A1 (en) 1991-02-27
EP0485430B1 (en) 1998-09-16
DE69032662D1 (de) 1998-10-22
ATE171042T1 (de) 1998-10-15
FI920450A7 (fi) 1992-01-31
US5730980A (en) 1998-03-24
PT94869B (pt) 1997-04-30
AU645515B2 (en) 1994-01-20
US6297049B1 (en) 2001-10-02
EP0485430A4 (en) 1993-03-03
PT94869A (pt) 1991-04-18
CA2022429C (en) 1998-12-01
JP2744130B2 (ja) 1998-04-28
DE69032662T2 (de) 1999-03-11
GR1003164B (el) 1999-07-05
CA2022429A1 (en) 1991-02-02
AU6146190A (en) 1991-03-11
JPH05501399A (ja) 1993-03-18
DK0485430T3 (da) 1999-06-14
FI920450A0 (fi) 1992-01-31
US6495332B2 (en) 2002-12-17
US6045795A (en) 2000-04-04
WO1991001639A1 (en) 1991-02-21
US20020034509A1 (en) 2002-03-21
EP0485430A1 (en) 1992-05-20

Similar Documents

Publication Publication Date Title
GR900100582A (el) Μέ?οδοι και συν?έσεις για την βελτίωση των συμπτωμάτων της σήψης.
PT751781E (pt) Utilizacao de anticorpos monoclonais ou ligandos oligomericos soluveis no fabrico de um medicamento para a prevencao ou tratamento de desordens neoplasicas
ES2227527T3 (es) Un factor de crecimiento de queratinocitos (kgf) truncado que tiene actividad biologica aumentada.
DE3583008D1 (de) Pharmazeutische zusammensetzungen von dihydrocodeine/ibuprofen und verfahren.
UA26403A (uk) Похідhі n-заміщеhого 4-феhіл-4-піперидиhкарбоксаміду та їх фармацевтичhо прийhятhі солі, що проявляють аhестезувальhу та аhальгезувальhу дію, спосіб їх одержаhhя та фармацевтичhа композиція
FI833605A0 (fi) Ny oral mopidamolprodukt
ATE234108T1 (de) Therapeutikum zur unterdrückung von schnarchgeräuschen
NO177526C (no) Fremgangsmåte for fremstilling av farmasöytisk aktive konjugater
ATE105484T1 (de) Aminderivate von folsaeure analogen.
MA24794A1 (fr) D-methadone, un analgesique nonopioique
ES536055A0 (es) Un procedimiento para la produccion de un complejo covalentemente enlazado de heparina-antitrombina-iii
DE69330352D1 (de) Mittel und methoden zur verbesserung der keratinocytenadhäsion an der haut
ATE72569T1 (de) Verfahren zur konjugierung von metallothionein mit biologisch aktiven molekuelen.
DE69534601D1 (de) Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
DE69327248D1 (de) Verfahren zur behandlung des symptomenkomplexes des prämenstruellen syndroms mit vitamin d oder vitamin d und calcium
BR9507067A (pt) Processo imunoterapêutico de tratamento de doenças cancerosas pro administração de gama-globulinas
DE69636527D1 (de) Antigenes protein aus malassezia
DE69729201T2 (de) Sulfonfluoride zur behandlung von der alzheimerischen krankheit
KR900011477A (ko) 항-트립타아제 항체 및 이것을 사용한 후천성 면역결핍증 치료용 조성물
DE69434220D1 (de) Verfahren zur verhütung der nebenwirkungen und unempfindlichkeit gegenüber therapeutischen verwendungen von toxinen
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
GR1000305B (el) Μεθοδος παρασκευης συνθεσεως για την ελαττωση της φλεβεκτασιας.
DE69228869D1 (de) Stabilisierte antikörperfragmente
KR920009403A (ko) 수면장해 치료용 이미다조벤조디아제핀

Legal Events

Date Code Title Description
MA Right expired